Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 14/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30441586 | 1.00 | L3MBTL1 (0.57) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL11964359 | 0.82 | NPC1 (0.43) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL25600283 | 0.81 | JAK2 (0.52) | PIK3C3JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL2642300 | 0.81 | L3MBTL1 (0.57) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL13165570 | 0.81 | TYK2 (0.66) | L3MBTL1PIK3C3JAK2JAK1TYK2 | |
| SCHEMBL91475 | 0.81 | ALDH1A1 (0.60) | L3MBTL1PIK3C3ALDH1A1CYP1A2 | |
| SCHEMBL19728666 | 0.80 | TYK2 (0.53) | TYK2ALDH1A1ACVRL1 | |
| SCHEMBL18785787 | 0.80 | LMNA (0.53) | L3MBTL1CYP1A2 | |
| SCHEMBL16311114 | 0.80 | JAK2 (0.53) | L3MBTL1JAK2JAK1TYK2ALDH1A1 | |
| SCHEMBL12975420 | 0.79 | L3MBTL1 (0.55) | L3MBTL1PIK3C3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4430042-B1 | 6-HETERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12522583-B2 | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240360132-A9 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240254125-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| CN-118201928-A | 6-Heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | 艾捷斯治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11970494-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240101559-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023009708-A1 | HETEROARYLOXY TRIAZOLO- AND IMIDAZO-AZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| EP-4041236-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2021226261-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3876930-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021067682-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067682-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | L3MBTL1 3614/4885PIK3C3 137/4885JAK2 2/4885 |
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | CDK1, CDK11A, CDK11B | L3MBTL1 2881/4885PIK3C3 594/4885JAK2 40/4885 |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | L3MBTL1 1749/4885PIK3C3 49/4885JAK2 1/4885 |
| US-20240101559-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | CDK1, CDK11B, CDK11A | L3MBTL1 2326/4885PIK3C3 434/4885JAK2 38/4885 |
| US-11970494-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | L3MBTL1 1749/4885PIK3C3 49/4885JAK2 1/4885 |
| US-20240360132-A9 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | CDK1, CDK11B, CDK11A | L3MBTL1 2326/4885PIK3C3 434/4885JAK2 38/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | L3MBTL1 1749/4885PIK3C3 49/4885JAK2 1/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | L3MBTL1 3276/4885PIK3C3 4718/4885JAK2 1856/4885 |
| US-20240254125-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | L3MBTL1 1749/4885PIK3C3 49/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.